Nebenwirkungen · Lojuxta
Lojuxta 2 mg hard capsules Lojuxta 5 mg hard capsules Lojuxta 10 mg hard capsules Lojuxta 20 mg hard capsules · Abschnitt 4.8 · PDF-Seite 14
HOS-127393 · Präparat HOS-096397
Table 4: Frequency of adverse reactions in HoFH patients System organ class Frequency Adverse reaction Infections and infestations Common Gastroenteritis Metabolism and nutrition Very common Decreased appetite* disorders Not known Dehydration Nervous system disorders Common Dizziness Headache Migraine Gastrointestinal disorders Very common Diarrhoea* Nausea* Vomiting* Abdominal discomfort Dyspepsia Abdominal pain* Abdominal pain upper* Flatulence* Abdominal distension Constipation Common Gastritis Rectal tenesmus Aerophagia Defaecation urgency Eructation Frequent bowel movements* Gastric dilatation Gastric disorder Gastro-oesophageal reflux disease Haemorrhoidal haemorrhage Regurgitation Hepatobiliary disorders Very common Alanine aminotransferase increased* Aspartate aminotransferase increased* Common Transaminases increased* Hepatic steatosis* Hepatotoxicity Hepatomegaly* Blood alkaline phosphatase increased Skin and subcutaneous tissue Common Ecchymosis disorders Papule Rash erythematous Xanthoma Not known Alopecia Musculoskeletal and connective Not known Myalgia tissue disorders General disorders and Common Fatigue administration site conditions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-25T14:24:00Z · SHA-256 56c36935b5cda4380e359902f1acbc5ec5bb081beeb96ca75e5ad86521fcd98c · Passage ce7adda7ef4341b811b4f7f3ca68291f1ec1b0a329d59cd49b11ba32adeb9e8f · Zeichen 1404–4603 im Abschnitt